Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) today. The company’s ...

Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...

Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

For the Bristol Myers Squibb (BMS) treasury function, innovation has long been fundamental. Still, after integrating with ...

US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...